FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden

Musa Yilmaz; Naval Daver; Gautam Borthakur; Tapan Kadia; Courtney DiNardo; Rashmi Kanagal-Shamanna; Sanam Loghavi; Betul Oran; Uday R. Popat; Sherry Pierce; Elias Jabbour; Nicholas J. Short; Ghayas Issa; Maro Ohanian; Marina Konopleva; Keyur Patel; Hagop Kantarjian; Farhad Ravandi

doi:10.1002/ajh.26202

FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden

Musa Yilmaz, Naval Daver, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Rashmi Kanagal-Shamanna, Sanam Loghavi, Betul Oran, Uday R. Popat, Sherry Pierce, Elias Jabbour, Nicholas J. Short, Ghayas Issa, Maro Ohanian, Marina Konopleva, Keyur Patel, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	E275-E279
Journal	American journal of hematology
Volume	96
Issue number	8
DOIs	https://doi.org/10.1002/ajh.26202
State	Published - Aug 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26202

Cite this

Yilmaz, M., Daver, N., Borthakur, G., Kadia, T., DiNardo, C., Kanagal-Shamanna, R., Loghavi, S., Oran, B., Popat, U. R., Pierce, S., Jabbour, E., Short, N. J., Issa, G., Ohanian, M., Konopleva, M., Patel, K., Kantarjian, H., & Ravandi, F. (2021). FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. American journal of hematology, 96(8), E275-E279. https://doi.org/10.1002/ajh.26202

FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. / Yilmaz, Musa ; Daver, Naval ; Borthakur, Gautam et al.
In: American journal of hematology, Vol. 96, No. 8, 01.08.2021, p. E275-E279.

Research output: Contribution to journal › Letter › peer-review

Yilmaz, M , Daver, N , Borthakur, G , Kadia, T , DiNardo, C , Kanagal-Shamanna, R , Loghavi, S , Oran, B , Popat, UR, Pierce, S, Jabbour, E , Short, NJ , Issa, G , Ohanian, M, Konopleva, M, Patel, K , Kantarjian, H & Ravandi, F 2021, 'FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden', American journal of hematology, vol. 96, no. 8, pp. E275-E279. https://doi.org/10.1002/ajh.26202

@article{c74c7169e5d6479e8611bf462edfeae3,

title = "FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden",

author = "Musa Yilmaz and Naval Daver and Gautam Borthakur and Tapan Kadia and Courtney DiNardo and Rashmi Kanagal-Shamanna and Sanam Loghavi and Betul Oran and Popat, {Uday R.} and Sherry Pierce and Elias Jabbour and Short, {Nicholas J.} and Ghayas Issa and Maro Ohanian and Marina Konopleva and Keyur Patel and Hagop Kantarjian and Farhad Ravandi",

note = "Funding Information: Elias Jabbour reports research grants and consultancy from Abbvie, Adaptive biotechnology, Amgen, BMS, Pfizer, Takeda. Funding Information: This work was supported in part by the MD Anderson Cancer Centre Support Grant (CCSG) CA016672. Funding Information: Ghayas Issa reports grants and personal fees from Novartis, grants from Syndax, grants from Celgene. Funding Information: Tapan Kadia reports personal fees from Novartis, grants and personal fees from Pfizer, grants from BMS, grants and personal fees from Abbvie, grants and personal fees from Genentech, grants and personal fees from JAZZ, grants from Amgen, grants from AstraZeneca; Celgene: research grant; Incyte: research grant; Ascentage: research grant. Funding Information: Musa Yilmaz reports research funding from Pfizer and Daiichi Sankyo. ",

year = "2021",

month = aug,

day = "1",

doi = "10.1002/ajh.26202",

language = "English (US)",

volume = "96",

pages = "E275--E279",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden

AU - Yilmaz, Musa

AU - Daver, Naval

AU - Borthakur, Gautam

AU - Kadia, Tapan

AU - DiNardo, Courtney

AU - Kanagal-Shamanna, Rashmi

AU - Loghavi, Sanam

AU - Oran, Betul

AU - Popat, Uday R.

AU - Pierce, Sherry

AU - Jabbour, Elias

AU - Short, Nicholas J.

AU - Issa, Ghayas

AU - Ohanian, Maro

AU - Konopleva, Marina

AU - Patel, Keyur

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

N1 - Funding Information: Elias Jabbour reports research grants and consultancy from Abbvie, Adaptive biotechnology, Amgen, BMS, Pfizer, Takeda. Funding Information: This work was supported in part by the MD Anderson Cancer Centre Support Grant (CCSG) CA016672. Funding Information: Ghayas Issa reports grants and personal fees from Novartis, grants from Syndax, grants from Celgene. Funding Information: Tapan Kadia reports personal fees from Novartis, grants and personal fees from Pfizer, grants from BMS, grants and personal fees from Abbvie, grants and personal fees from Genentech, grants and personal fees from JAZZ, grants from Amgen, grants from AstraZeneca; Celgene: research grant; Incyte: research grant; Ascentage: research grant. Funding Information: Musa Yilmaz reports research funding from Pfizer and Daiichi Sankyo.

PY - 2021/8/1

Y1 - 2021/8/1

UR - http://www.scopus.com/inward/record.url?scp=85105314754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105314754&partnerID=8YFLogxK

U2 - 10.1002/ajh.26202

DO - 10.1002/ajh.26202

M3 - Letter

C2 - 33891709

AN - SCOPUS:85105314754

SN - 0361-8609

VL - 96

SP - E275-E279

JO - American journal of hematology

JF - American journal of hematology

IS - 8

ER -

FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this